Company news
Lexaria Bioscience Corp. news in 2026
Lexaria Bioscience Corp.'s news releases, calls and decks from 2026, newest first.
Lexaria Celebrates its 70th Patent Award
October 28, 2026
Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule
October 21, 2026
Lexaria Announces Results From Animal Study GLP-1-A26-1
October 15, 2026
Lexaria Updates Financial Position
September 17, 2026
Lexaria Bioscience Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
September 9, 2026
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
September 9, 2026
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
September 8, 2026
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 4, 2026
Lexaria Receives USD$2.6 Million Tax Rebate Payment
September 1, 2026
Lexaria Enters a Material Transfer Agreement With PegBio
August 13, 2026
Lexaria Announces Effective Date for Reverse Stock Split
July 30, 2026
Lexaria Updates Business Development
July 6, 2026
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
June 25, 2026
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
June 23, 2026
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
June 9, 2026
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
June 3, 2026
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
May 19, 2026
Lexaria Bioscience Releases Second Episode of Investor Video Series
May 7, 2026
Lexaria Updates Progress on Human Study #7
May 5, 2026
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
May 1, 2026
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
April 22, 2026
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
April 14, 2026
Lexaria to Begin New Human Clinical Study in GLP-1
March 31, 2026
Lexaria Announces New R&D Plans for 2026
March 4, 2026
Lexaria Announces Positive Final Results From Human Pilot Study #5
February 5, 2026
Lexaria Awarded Six Additional Patents
January 22, 2026
Lexaria Releases Annual Letter from the CEO
January 12, 2026